01—Abstract
Summary
Summary of the 10-K/A filed October 3, 2003. Cited figures are marked; the original filing is the authoritative source.
This Form 10-K/A filing for IDEC Pharmaceuticals Corporation as of December 31, 2002, primarily serves to re-file a redacted Commercial Supply Agreement with Baxter Pharmaceutical Solutions LLC.
While it does not introduce new financial information or material events post the original filing date, it provides an overview of the company's corporate structure and extensive list of agreements. Investors should note that this is an amended filing focused on a specific contractual document rather than a comprehensive update of the company's financial performance or strategic initiatives for the fiscal year 2002.
02—Key points
Key Highlights
- The filing is an amended 10-K (10-K/A) specifically to re-file a redacted Commercial Supply Agreement between IDEC Pharmaceuticals Corporation and Baxter Pharmaceutical Solutions LLC, dated June 1, 2002.
- The company was incorporated in Delaware with its principal executive offices in San Diego, California.
- IDEC Pharmaceuticals Corporation was an accelerated filer as of the reporting period.
- As of June 30, 2002, the aggregate market value of the voting stock held by non-affiliates was approximately $5.2 billion.
- As of January 31, 2003, the company had over 154.6 million shares of common stock issued and outstanding.
- The filing lists a vast array of agreements, including purchase agreements, stock option plans, license agreements, and collaborative development agreements, indicating a complex web of partnerships and financing activities.
- Key certifications pursuant to the Sarbanes-Oxley Act of 2002 (Sections 302 and 906) are included, demonstrating compliance with new regulatory requirements.
03—Questions
Frequently Asked Questions
What is the primary purpose of this amended 10-K filing?
This Form 10-K/A is primarily filed to re-file a redacted Commercial Supply Agreement dated June 1, 2002, between IDEC Pharmaceuticals Corporation and Baxter Pharmaceutical Solutions LLC. It does not introduce new financial data or events that occurred after the original filing date of the 10-K.
What is the overall financial health indicated by this filing?
This specific amended filing does not provide detailed financial statements or performance metrics for the fiscal year 2002. Its focus is on a specific contract. Therefore, assessing the company's overall financial health would require reviewing the original 10-K filing or subsequent financial reports.
Are there any significant operational changes or new product developments mentioned?
No, this amended filing is procedural and focuses on a supply agreement. It does not contain information about significant operational changes or new product developments. Such details would typically be found in the Management's Discussion and Analysis section of the original 10-K report.
What is the significance of the listed exhibits and agreements?
The extensive list of exhibits, including various purchase agreements, stock plans, and collaborative development agreements, indicates a company actively engaged in strategic partnerships, financing, and research and development activities. These agreements are crucial for understanding the company's business model and potential future growth drivers.
04—Continue